Enhanced Oncolytic Virus System with AI-Powered Personalized Cancer Therapy

A novel system integrating oncolytic viruses with advanced technologies like AI, IoT, blockchain, and graphene-based materials to provide personalized, effective, and secure cancer treatment.

Despite the progress in oncolytic virus development, limitations remain in terms of optimal dosing regimens, patient data management, and treatment efficacy monitoring. The present inventive concept addresses these challenges by synergistically combining the patented oncolytic virus with cutting-edge technologies.

The enhanced oncolytic virus system comprises a recombinant oncolytic virus with a truncated fragment of HSV1-TK, a machine learning module for predicting optimal dosing regimens, a blockchain-based patient data management system, a graphene-based material for viral stability and delivery, and an IoT sensor module for real-time monitoring of tumor response. The system enables personalized cancer therapy by leveraging AI-driven predictions, secure patient data management, and targeted treatment administration.

The new claims introduce a synergistic combination of distinct technologies, providing a non-obvious solution that significantly improves the safety and anticancer effect of oncolytic viruses. The integration of AI, blockchain, IoT, and graphene-based materials with the patented oncolytic virus constitutes a novel and inventive step beyond the original patent.

Alternative embodiments may include the use of different AI algorithms, blockchain platforms, or graphene-based materials. Variations could involve integrating the oncolytic virus with other advanced technologies, such as nanotechnology or synthetic biology, to further enhance treatment outcomes.

The enhanced oncolytic virus system has significant commercial potential in the cancer treatment market, with potential applications in personalized medicine, precision oncology, and targeted therapy. The system's ability to provide secure, effective, and personalized treatment makes it an attractive solution for pharmaceutical companies, hospitals, and research institutions.